Information  X 
Enter a valid email address

Psych Capital PLC (PSY)

  Print   

Wednesday 25 May, 2022

Psych Capital PLC

Intention to Float

RNS Number : 6748M
Psych Capital PLC
25 May 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

 

This announcement is an advertisement and not an admission document or a prospectus. This announcement is not and does not constitute or form part of, and should not be construed as, an offer of securities for subscription or sale in any jurisdiction nor a solicitation of any offer to buy or subscribe for, any securities in any jurisdiction, nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This announcement does not constitute a recommendation regarding any securities. Prospective investors should not subscribe for or purchase any securities referred to in this announcement except in compliance with applicable securities laws and regulation and on the basis of the information in the final admission document ("Admission Document") intended to be published by Psych Capital plc, and the proposed admission of the entire issued and to be issued ordinary share capital of the Company to trading on the AQSE Growth Market.

 

Psych Capital Plc

("Psych" or the "Company")

 

Intention to Float on Aquis

 

Investing in psychedelics to revolutionise mental health treatment

 

Psych Capital Plc, the psychedelic medicines media and investment company, announces its intention to seek admission of the entire issued and to be issued ordinary share capital of the Company to the AQSE Growth Market ("Admission").

Key Highlights

· The Company currently has exposure to key segments of the medical psychedelic sector through both strategic acquisitions and investments, including:

Clinical research in connection with the development of psychedelic medicines used to treat addiction;

Data collection in relation to developments in the psychedelic sector (including, the legal framework, commerce and science); and

Media and communications platform for the medical psychedelic industry

· The Company intends to identify, fund and support the building of future companies across three core pillars: therapeutic treatments, drug development, and data/artificial intelligence

· The Company will leverage its portfolio of brands and network of experts to identify early-stage opportunities in the medical psychedelic industry

· The Psych Platform is a global B2B resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events

PSYCH Symposium events generate strong revenue through sponsorship and ticket sales

 

Market Opportunity

The market opportunity in the nascent and growing psychedelics' space is being harnessed by a growing base of institutional investors seeking to establish and scale businesses in a landscape showing scientific and commercial promise. While capital invested in psychedelic companies is over US$2 billion, the current value of medical businesses surpasses US$10 billion, with ATAI Life Sciences' initial public offering (IPO) last year which made it the most valuable publicly-traded business among the 47 publicly-traded businesses in the sector, currently valued at US$928 million (as of 14 February 2022). Biotech and pharmaceutical companies continue to dominate businesses within the sector, though there is a growing base - and appetite for - research clinics, therapy providers and software infrastructure. (Source: The Psychedelics as Medicine Report 3rd Edition 2021.)

 

In modelling the medical psychedelics market, the Company is focused on therapy training and services, to encapsulate the current market condition. In 2021, with ketamine the only compound used off-label widely for the treatment of mental health conditions, and esketamine for Treatment-Resistant Depression, ketamine-assisted-therapy dominates the market. The Company expects compassionate use to increasingly include psilocybin and MDMA, with policy and health advocates being strong proponents of such therapies. MDMA is currently available for compassionate use in Israel, Switzerland and Canada.

 

Current Platforms and Investments

Investments

Psych has undertaken an investment in Awakn, a Canadian NEO Exchange listed psychedelics research and clinical group, with operations in the UK and Europe.

 

The Company will particularly seek to focus on identifying and supporting, strategically and financially early-stage companies that provide ancillary products and services which serve the medical psychedelic sector, primarily in the UK, across Europe and other internationally recognised  jurisdictions (such as Canada), which have well-developed and reputable laws and regulations supporting the research and production of psychedelic medicines.

 

Platforms

PSYCH is a business-to-business data, intelligence and media platform for the psychedelic science and healthcare industry, and it operates the website, https://psych.global/. PSYCH is a global B2B resource for data, intelligence and insights, servicing the industry through publications, newsletters and engaging events. PSYCH has amassed a significant global B2B audience, with over 20,000 subscribers to the platform.

 

As a business-to-business media and content platform, the Psych Platform also produces the PSYCH Symposium, a premium Live Event series.

PSYCH Symposium

To date PSYCH events have featured over 80 speakers, that include Professor David Nutt, Christian Angermayer and Rick Doblin, welcomed 3,000+ delegates and generated strong revenue through sponsorship and ticket sales. 

The PSYCH Symposium, held on Wednesday 11 May 2022 at the National Gallery was Sold Out. The Symposium attended by over 300 attendees. Further details on the event can be found at: https://www.psychsymposium.com/ .

The Company is pleased with the success of the event that is indicative of the support and reach of PSYCH. The success of the event was a result of the Psych Capital team's commitment and continued support by a host of sponsors - https://www.psychsymposium.com/sponsorship - in the psychedelics sector.

For further information on Psych Capital please visit https://psych.capital/  

 

Directors

 

William Christopher Potts (Chief Executive Officer)

William Potts is the co-founder of Psych Capital Plc. He has been an active investor in psychedelics healthcare since 2020, and brings an extensive network of high net worth and institutional investors to the table. William has been specifically focused on the healthcare sector for a number of years.

 

Stephen Murphy (Executive Director) 

Stephen Murphy is the co-founder of Psych Capital Plc. He is also the CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry's best known B2B companies and brands including Prohibition Partners and Cannabis Europa. Stephen's background is in technology, digital media and corporate finance.

 

Proposed Directors

Joseph Tregonning Colliver (Non-Executive Director )

Joseph built and led a team at one of the UK's first publicly listed CBD wellness and medicinal cannabis company. Joseph led the reverse-takeover via a scheme of arrangement of a listed Canadian CBD wellness business, merging the two companies and listing the combined group on the CSE and AQSE. In his CFO / COO role he had accountability for all regulatory matters, leading the company's novel food application process with the Food Standards Agency, obtaining a Home Office controlled drugs licence, and liaising with regulators such as Trading Standards, VMD, MHRA. Joseph had P&L accountability for the analytical laboratory (achieving ISO 107025) and wholesale CBD extraction operations and sales in Europe, as well as finance, HR, legal, fund-raising, investor relations, and M&A. Joseph was also responsible for the research partnership with King's College London and recruited and oversaw the Scientific Advisory Board. Prior to this, Joseph spent 10 years at WPP, holding senior finance, commercial and client facing leadership roles across several operating companies, after qualifying as a chartered accountant in audit practice.

 

William Potts, Co-founder and CEO of Psych Capital commented:

 

"We are excited by the opportunity to capitalise on the rapidly expanding psychedelic medicines industry. We are particularly well placed to generate returns as we leverage our knowledge and experience to provide access and visibility to early stage deals not usually available to investors. Importantly, we believe that our experience, philosophy and industry know how sets us apart. We look forward to beginning this new chapter and highly anticipate taking advantage of the ever-increasing opportunities available in this very exciting market."

 

For further information, please contact:

 

Psych Capital Plc


Stephen Murphy, Executive Director

via Walbrook PR

Will Potts, Chief Executive Officer


 


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or [email protected]

Nick Rome / Tom Cooper

Mob: +44 (0) 7748 325 236 / +44 (0) 7971 221 972

 

About Psych Capital Plc

Psych Capital Plc identifies, funds and aims to support the building of British and European companies across three core pillars: therapeutic treatments, drug development, and data/AI. Its mission is to support a new wave of innovators who are well positioned to challenge the status-quo and revolutionise how society deals with mental health conditions.

 

Through a network of analysts with deep industry knowledge and capital markets expertise, Psych Capital is focussed on developing a rigorously selected portfolio of industry leading companies at the intersection of psychedelic medicine and technology.

 

The Psych Platform is a business-to-business media and content platform for the psychedelic science and healthcare industry, and it operates the website, https://psych.global/. The Psych Platform is a global B2B resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events. The Psych Platform has amassed a significant global B2B audience, with over 20,000 subscribers to the platform.

 

As a business-to-business media and content platform, the Psych Platform also produces the PSYCH Symposium, a premium Live Event series.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXDZLFLLELBBBE

a d v e r t i s e m e n t